An Open Study of Acebutolol, Given as a Single Daily Dose in the Management of Hypertension in the Chulalungkorn Hospital, Thailand

Abstract

In an open study of fifteen patients with essential hypertension, acebutolol, a cardioselective β1-adrenoceptor antagonist given orally once daily at dosages of between 400 mg and 1200 mg, produced a substantial and progressive reduction in systolic and diastolic arterial pressure and in the tension time index both in the lying and standing position over the 3 months of the trial. The changes from pre-trial values of blood pressure assessments were statistically significant (p<0.001). No side-effects were reported and laboratory monitoring of biological parameters revealed no untoward effects of treatment.